We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMERGO
RNS Number : 9319N
Ergomed plc
14 August 2017
PRESS RELEASE
Ergomed notes announcement by co-development partner, CEL-SCI, of FDA removal of clinical hold on Phase 3 clinical trial with Multikine in head and neck cancer
London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a specialised pharmaceutical services and drug development company, notes that its co-development partner CEL-SCI has announced that the US Food and Drug Administration (FDA) has removed the clinical hold on the current Phase 3 study with Multikine in head and neck cancer.
All clinical trial activities can now be resumed. Nine-hundred and twenty-eight (928) newly diagnosed head and neck cancer patients have been enrolled in this Phase 3 study and all the patients who have completed treatment continue to be followed for protocol-specific outcomes in accordance with the Study Protocol.
Dr. Dan Weng, Chief Executive Officer of Ergomed, said: "We're very pleased to hear that the Phase 3 study of Multikine in head and neck cancer has been approved for continuation by the FDA. Multikine addresses a significant unmet medical need and we look forward to continuing to work with CEL-SCI on what is the largest ever Phase III study in head and neck cancer."
The full announcement from CEL-SCI can be found on its website: www.cel-sci.com.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503205 Dan Weng (Chief Executive Officer) Stephen Stamp (Chief Financial Officer) Numis Securities Limited Tel: +44 (0) 20 7260 1000 Michael Meade / Freddie Barnfield (Nominated Adviser) James Black (Joint Broker) N+1 Singer Tel: +44 (0) 20 7496 3000 Alex Price (Joint Broker) Consilium Strategic Communications Tel: +44 (0) - for UK enquiries 20 3709 5700 Chris Gardner / Mary-Jane ergomed@consilium-comms.com Elliott Ivar Milligan / Philippa Gardner MC Services - for Continental Tel: +49 211 European enquiries 5292 5222 Anne Hennecke
About Ergomed
Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUMPRUPMGGC
(END) Dow Jones Newswires
August 14, 2017 07:31 ET (11:31 GMT)
1 Year Ergomed Chart |
1 Month Ergomed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions